Myeloproliferative neoplasms are a group of rare blood cancers in which the bone marrow becomes overactive, causing the cells to develop and function abnormally. MPNs originate in the bone marrow: the soft tissue in the middle of your bones where blood cells are produced. Myeloproliferative neoplasms can strike anyone at any age. The three main MPNs are myelofibrosis, polycythemia vera, and essential thrombocythemia. There are several treatment options available to MPN patients, including Jakafi® (ruxolitinib), INREBIC®(fedratinib), BESREMi® (ropeginterferon alfa-2b), VONJO® (pacritinib), and Ojjaara (momelotinib). Clinical trials are underway for other drugs for all three MPNs.
Learn more about: